For decades, the field of oncology has heavily relied on traditional investigative methods such as karyotyping, followed by the incorporation of FISH technology and, more recently, sequencing. However, upon closer examination of the data generated over the past three to five decades, it becomes apparent that a significant category of structural variants remains largely unexplored, limiting our understanding of their impact on oncogenesis, prognosis, therapeutic resistance, relapse, and metastatic disease. Dr. Kohle shares how he has utilized the optical genome mapping (OGM) technique to unveil hidden structural variants.